Combining an Anti-LAG-3 Antibody With Nivolumab in Melanoma

September 13, 2017
Paolo A. Ascierto, MD

Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses the initial efficacy findings for the anti-LAG-3 antibody BMS-986016 plus nivolumab in patients with immunotherapy-relapsed/refractory melanoma.